China Liquid Biopsy Market (2025-2030)
The China Liquid Biopsy Market was valued at $213.3 Million in 2025 and projected to reach to $449.1 Million by 2030, representing a compound annual growth rate of 16.1%. China's liquid biopsy market is positioned for exceptional growth through 2030, driven by escalating cancer incidence, expanding healthcare expenditure, and rapid adoption of advanced diagnostic technologies.
China Liquid Biopsy Market Trends and Insights
- This robust growth trajectory reflects China's increasing adoption of non-invasive diagnostic technologies and rising healthcare investments across oncology and genetic screening applications.
- China's market expansion is driven by growing cancer prevalence, expanding healthcare infrastructure, and government support for precision medicine initiatives. The liquid biopsy sector in China benefits from a large patient population and accelerating clinical adoption of blood-based biomarker testing.
- China's healthcare system is increasingly integrating liquid biopsy solutions into routine diagnostic protocols, particularly for early cancer detection and treatment monitoring.
- By 2030, China is expected to solidify its position as a leading market for liquid biopsy technologies in the Asia Pacific region, with sustained double-digit growth fueled by technological advancement and rising healthcare spending..
Key Market Statistics
- CAGR (2025-2030) 16.1% CAGR
- Market Size, 2025 ~USD 213.3 Million
- Forecast, 2030 ~USD 449.1 Million
- Country China
China Liquid Biopsy Market Overview
Rapid Market Expansion :
China's liquid biopsy market is projected to grow from $213.3 million in 2025 to $449.1 million by 2030, representing a 16.1% CAGR—significantly outpacing the global growth rate of 11.8%.
Rising Cancer Prevalence :
Increasing incidence of cancer across China's aging population is driving demand for early detection and non-invasive diagnostic solutions, positioning liquid biopsy as a critical healthcare priority.
Healthcare Investment Growth :
China's substantial investments in healthcare infrastructure and diagnostic technology adoption are accelerating the integration of liquid biopsy across oncology centers, hospitals, and genetic screening facilities nationwide.
Non-Invasive Technology Adoption :
Growing patient preference for non-invasive diagnostic methods and improved reimbursement policies are driving widespread adoption of liquid biopsy testing in China's healthcare system.
China Liquid Biopsy Market Dynamics
- The market's 16.1% CAGR reflects strong government support for precision medicine initiatives and increasing awareness among healthcare providers and patients regarding early cancer detection benefits. Key growth catalysts include China's aging demographic, rising disposable incomes enabling premium diagnostic access, and strategic partnerships between domestic and international biotech firms.
- As reimbursement frameworks mature and clinical validation strengthens, liquid biopsy adoption will extend beyond oncology into prenatal screening and genetic risk assessment, establishing China as a major global market contributor..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- China's liquid biopsy market is valued at $213.3 million in 2025 and is forecast to grow to $449.1 million by 2030, representing a 16.1% CAGR.
- China's market growth is driven by rising cancer incidence, government precision medicine initiatives, and expanding healthcare infrastructure investment.
- China's adoption of liquid biopsy technologies is accelerating in oncology diagnostics, early detection, and treatment monitoring applications.
- China is positioned as a key growth engine in the Asia Pacific liquid biopsy market, with sustained double-digit expansion through 2030.
Liquid Biopsy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CIRCULATING TUMOR DNA (Circulating Biomarker Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 11.8% from 2025 to 2030 |
| Largest Segment | BLOOD (Sample Type) |
| Market Size Base Year (Billions) | ~USD 4.04 (2025) |
| Revenue Forecast (Billions) | ~USD 7.05 (2030) |
| Segments Covered | Product & Service, Circulating Biomarker Type, Technology, Application, Type, Clinical Application, Sample Type, End User |
China Liquid Biopsy Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product & Service
- Assay Kits
- Instruments
- Services
By Circulating Biomarker Type
- Cell-Free Dna
- Circulating Tumor Cells
- Circulating Tumor Dna
- Extracellular Vesicles
- Other Circulating Biomarkers
By Technology
- Multi-Gene Parallel Analysis Using Ngs
- Single-Gene Analysis Using Pcr Microarrays
By Application
- Cancer Applications
- Non-Cancer Applications
By Type
- Breast Cancer
- Colorectal Cancer
- Infectious Disease Testing
- Lung Cancer
- Melanoma
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Other Cancers
- Prostate Cancer
By Clinical Application
- Early Cancer Screening
- Recurrence Monitoring
- Therapy Selection
- Treatment Monitoring
By Sample Type
- Blood
- Other Sample Types
By End User
- Academic & Research Centers
- Hospitals & Physician Laboratories
- Hospitals & Physicians Laboratories
- Other End Users
- Reference Laboratories
Target Audience
- In Vitro Diagnostics (IVD) Manufacturers : Need China-specific market data to develop liquid biopsy product portfolios, establish manufacturing partnerships, and navigate regulatory pathways for market entry and expansion.
- Pharmaceutical & Biotech Companies : Require detailed China market insights to identify companion diagnostic opportunities, plan clinical trial strategies, and align oncology drug development with regional diagnostic adoption trends.
- Healthcare Investors & Private Equity : Seek comprehensive China market analysis to evaluate investment opportunities in liquid biopsy startups, diagnostic labs, and healthcare technology companies with high growth potential.
- Hospital Networks & Diagnostic Centers : Need market forecasts and adoption trends to make informed decisions about liquid biopsy service implementation, technology partnerships, and capital allocation for diagnostic infrastructure.
- Government & Healthcare Policy Makers : Require market intelligence to develop precision medicine policies, allocate healthcare budgets, and establish reimbursement frameworks that support liquid biopsy integration into China's healthcare system.
Key Companies in the China Liquid Biopsy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Vaccines (pediatric, hexavalent, travel and epidemic),Immunology & Inflammation,Rare Diseases & Neurology, |
| CONMED CORPORATION | United States | Public Company | Orthopedic sports medicine and power tools (BioBrace, Y-Knot, Hall, related disposables),General surgery and minimally invasive platforms (AirSeal, Buffalo Filter, endomechanical, electrosurgery),Endoscopic technologies and patient monitoring (GI therapeutics, ECG/EEG, defibrillation pads), |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, markers, localization, treatment),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| UNITED IMAGING HEALTHCARE CO., LTD. | China | Public Company | Magnetic Resonance Imaging,Computed Tomography,Molecular Imaging (PET/CT, SPECT), |
| NATERA, INC. | United States | Public Company | Oncology MRD and CGP (Signatera, Latitude, Altera, Empower oncology use),Women’s health (Panorama, Horizon, Fetal Focus, Vistara, Anora),Transplant and nephrology (Prospera, Renasight), |
| GUARDANT HEALTH | United States | Public Company | Guardant360 liquid portfolio (CDx and Guardant360 Liquid),Guardant Reveal and minimal residual disease testing,Guardant360 Tissue and tissue-based profiling, |
| MYRIAD GENETICS, INC. | United States | Public Company | Hereditary and Companion Diagnostics (MyRisk, BRACAnalysis CDx, MyChoice CDx),Oncology Prognostics and Tumor Profiling (Prolaris, EndoPredict, Precise Tumor),Women’s Health and Prenatal (Prequel, Foresight, SneakPeek, FirstGene), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Arrays and genotyping products, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual and reproductive health assays, |
| EXACT SCIENCES CORPORATION | United States | Private Company | Cologuard and Cologuard Plus,Oncotype DX breast and colon tests,Hereditary and risk assessment tests (Riskguard, Cancerguard, Genetic Testing), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| GRAIL, INC. | United States | Public Company | Galleri multi-cancer early detection screening,Diagnostic aid for suspected cancer,Precision oncology and MRD/monitoring (RUO methylation platform), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Life Science segment,Clinical Diagnostics segment, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation analyzers and reagents,Urinalysis, blood gas/electrolyte, and related analyzers, |
| MDXHEALTH | Belgium | Public Company | Confirm mdx (prostate cancer tissue test),ExoD (non-invasive urine prostate cancer test),Genomic Prostate Score collaboration, |
| PERSONALIS, INC. | United States | Public Company | Pharma and biopharma research services (ImmunoID NeXT, exome/transcriptome projects),MRD and clinical liquid biopsy (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling and Dx (NeXT Dx and related tests), |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees, operating as a public company in the healthcare and drug development sector.
CONMED CORPORATION
CONMED Corporation is a U.S.-based public company founded in 1970 with 3,900 employees that manufactures and distributes medical devices and equipment.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. company founded in 1985 with 7,070 employees focused on diagnostic and surgical medical devices.
UNITED IMAGING HEALTHCARE CO., LTD.
United Imaging Healthcare Co., Ltd. is a Chinese public company founded in 2011 with 8,703 employees specializing in medical imaging equipment and solutions.
NATERA, INC.
Natera, Inc. is a U.S. public company founded in 2003 with 6,138 employees providing genetic testing and cell-free DNA analysis services.
GUARDANT HEALTH
Guardant Health is a U.S. public company founded in 2011 with 2,498 employees focused on liquid biopsy and genomic testing for cancer detection.
MYRIAD GENETICS, INC.
Myriad Genetics, Inc. is a U.S. public company founded in 1991 with 2,700 employees specializing in genetic testing and personalized medicine.
ILLUMINA, INC.
Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees that develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN N.V.
QIAGEN N.V. is a Dutch public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research tools.
EXACT SCIENCES CORPORATION
Exact Sciences Corporation is a U.S. private company founded in 1995 with 7,150 employees specializing in molecular diagnostics and cancer screening.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a U.S. public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical services.
GRAIL, INC.
GRAIL, Inc. is a U.S. public company founded in 2015 with 910 employees focused on early cancer detection through blood-based genomic testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952 with 7,450 employees manufacturing clinical diagnostics and life science research products.
SYSMEX CORPORATION
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees specializing in in vitro diagnostics and hematology analyzers.
MDXHEALTH
MDxHealth is a Belgian public company founded in 2003 with 364 employees providing molecular diagnostics and epigenetic testing services.
PERSONALIS, INC.
Personalis, Inc. is a U.S. public company founded in 2011 with 260 employees offering whole genome sequencing and cancer genomics analysis.
Reasons to Buy this Report
- Market Size & Growth Validation : Access precise market valuations for China ($213.3M in 2025, $449.1M in 2030) with detailed CAGR analysis to support investment decisions and competitive positioning strategies.
- Regional Performance Benchmarking : Compare China's 16.1% CAGR against the global 11.8% benchmark to identify outperformance drivers and understand China's strategic importance within your global portfolio.
- Localized Growth Driver Analysis : Gain insights into China-specific factors including cancer prevalence trends, healthcare investment patterns, and technology adoption rates that differentiate this market from other regions.
- Strategic Market Entry Planning : Leverage comprehensive China market data to develop targeted go-to-market strategies, identify key customer segments, and optimize resource allocation for market penetration.
- Competitive Intelligence : Understand China's unique regulatory environment, reimbursement landscape, and competitive dynamics to anticipate market shifts and maintain competitive advantage in this high-growth market.
Frequently asked questions
What is the current size of China's liquid biopsy market?
China's liquid biopsy market is valued at $213.3 million in 2025 and is expected to reach $449.1 million by 2030.
What is the projected growth rate for China's liquid biopsy market?
China's liquid biopsy market is projected to grow at a compound annual growth rate (CAGR) of 16.1% from 2025 to 2030.
What are the primary drivers of growth in China's liquid biopsy market?
China's market growth is driven by increasing cancer prevalence, government support for precision medicine, expanding healthcare infrastructure, and rising adoption of non-invasive diagnostic technologies.
Which applications are leading China's liquid biopsy market adoption?
China's liquid biopsy adoption is strongest in oncology diagnostics, early cancer detection, and treatment monitoring applications across major healthcare institutions.
How does China's liquid biopsy market compare to global trends?
China's liquid biopsy market is growing faster than the global average, with a 16.1% CAGR in China compared to the global CAGR of 11.8%, reflecting accelerated adoption and market maturation.
RESEARCH METHODOLOGY
The study involved estimating activities to determine the current size of the liquid biopsy market. Exhaustive secondary research was done to collect information on the liquid biopsy industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the liquid biopsy market.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| QIAGEN | Sales Manager |
| F. Hoffmann-La Roche Ltd. | Sales Executive |
Market Size Estimation
Liquid biopsy is a non-invasive method for diagnosing and monitoring diseases. Blood or other body fluids are collected to analyze cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or circulating tumor cells (CTCs).
Data Triangulation
After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand & supply sides.
Market Definition
Both top-down and bottom-up approaches were used to estimate and validate the liquid biopsy market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- Primary and secondary research have determined the revenues of leading players operating in the liquid biopsy market.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Stakeholders
- Manufacturers & Distributors of Liquid Biopsy Products
- Hospitals & Diagnostic Centers
- Reference Laboratories
- R&D Companies
- Research Laboratories and Academic Institutes
- Liquid Biopsy Service Providers
- Government Associations
- Venture Capitalists & Investors
Report Objectives
- To define, describe, segment, and forecast the liquid biopsy market, by product & service, circulating biomarker type, technology, application, clinical application, sample type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as acquisitions, collaborations, partnerships, agreements, and product launches & approvals in the liquid biopsy market
- To benchmark players within the liquid biopsy market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Get the Full Liquid Biopsy Market Report
Full forecast, segment splits, and company analysis for all Liquid Biopsy Market.
- US Liquid Biopsy Market
- Canada Liquid Biopsy Market
- Germany Liquid Biopsy Market
- UK Liquid Biopsy Market
- France Liquid Biopsy Market
- Italy Liquid Biopsy Market
- Spain Liquid Biopsy Market
- Japan Liquid Biopsy Market
- India Liquid Biopsy Market
- Brazil Liquid Biopsy Market
- Mexico Liquid Biopsy Market
- Rest Of Europe Liquid Biopsy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report